How to Trade HIMS on Hyperliquid

What Is Hims & Hers Health

Hims & Hers Health (NYSE: HIMS) is a telehealth company that has grown into the dominant direct-to-consumer healthcare platform in the United States. The company connects consumers with licensed medical professionals who can prescribe treatments across sexual health, hair loss, dermatology, mental health, and — most notably in recent quarters — weight management.

The numbers tell the growth story clearly. FY2025 revenue hit $2.35 billion, up 59% year-over-year, with $128 million in net income and over 2.5 million active subscribers. For 2026, management guided revenue of $2.7 billion to $2.9 billion. In February 2026, the company announced a $1.15 billion acquisition of Eucalyptus, an Australian digital health company operating across the UK, Germany, Japan, and Canada — a clear signal that international expansion is the next growth vector.

The business model is straightforward: Hims owns the customer relationship, manages the platform, and takes a margin on every consultation and prescription fulfilled. It is not a drug manufacturer. It is a distribution and access layer for healthcare, and that distinction matters for understanding both the opportunity and the risk.

Why HIMS Matters Right Now

HIMS has been one of the wildest equity stories of 2026. The stock collapsed over 50% in the first two months of the year after the FDA labeled the company's $49 compounded semaglutide pill an unlawful copycat of Novo Nordisk's Wegovy, followed by a patent infringement lawsuit from Novo and further FDA restrictions on compounded GLP-1 ingredients. The stock cratered from around $70 to under $16.

Then in March, Novo Nordisk and Hims reached a landmark deal. Novo dropped the lawsuit and agreed to let Hims distribute branded Wegovy injections and pills, plus Ozempic, directly through its platform. Hims agreed to stop advertising compounded GLP-1 products. The stock ripped from roughly $14 to over $22 in under two weeks, burning $546 million in short positions along the way.

Short interest had reached record levels near 35% of float before the deal, and the squeeze dynamics remain a factor. With the stock now around $24.77, the bull case centers on HIMS as an official branded GLP-1 distributor with a massive subscriber base and international expansion via Eucalyptus. The bear case points to compressed margins on branded drugs versus the lucrative compounding business that just died.

The HIP-3 Perpetual

HIMS trades on Hyperliquid as a HIP-3 perpetual futures contract, deployed on the xyz builder exchange. HIP-3 is Hyperliquid's protocol for permissionless perpetual markets — any builder who stakes the required HYPE can deploy a perp contract tracking any asset, from crypto tokens to equities like HIMS.

The mechanics are familiar to anyone who has traded perps: you get leveraged long or short exposure to the HIMS price without owning the underlying stock. The contract settles against an oracle price derived from the NYSE-listed equity, so the perp tracks real equity price action. This is a meaningful product for traders who want to express a view on HIMS outside traditional brokerage hours, from a crypto-native wallet, or with the composability that on-chain settlement provides.

HIP-3 markets collectively surpassed $1.43 billion in open interest across all deployed assets, making Hyperliquid one of the largest venues for this type of permissionless equity-linked derivative. The deployer's HYPE stake acts as a security bond — validators can slash it if the market is operated maliciously, which provides a trust layer without centralized listing committees.

Key Trading Considerations

HIMS is a high-beta name with multiple active catalysts pulling in opposite directions, which makes it interesting as a perp but demands discipline.

Volatility regime. The stock has swung from $70 to $16 and back to $25 in three months. That is extreme range for a $5 billion market cap healthcare company, driven by binary regulatory and partnership outcomes. Expect outsized moves around FDA announcements, Novo Nordisk product rollout updates, and quarterly earnings.

Short interest dynamics. With short interest that recently peaked above 35% of float, HIMS is structurally prone to squeezes. The March 2026 Novo deal triggered one of the largest short burns of the year. Any positive catalyst — an earnings beat, international expansion news, or a new branded drug partnership — could trigger similar mechanics. Conversely, a heavy short base also means there is conviction on the bear side, and fresh negative headlines can accelerate downside.

The branded pivot question. The core debate is whether Hims can maintain growth and margins after losing the compounding arbitrage. Compounded GLP-1s were high-margin products sold at a fraction of branded prices. Now HIMS distributes Novo's branded drugs, which carry lower platform margins. The Eucalyptus acquisition and expansion into new therapeutic categories are management's answer, but execution risk is real.

Liquidity awareness. As a newer HIP-3 market, the HIMS perp may have thinner order books than established Hyperliquid pairs. Check spread and depth before sizing positions, particularly during off-hours when equity markets are closed and price discovery shifts entirely to the perp.

Trading on Hyperliquid

Trade HIMS on Hyperliquid with up to 10x leverage.